Understanding how DUSP2 affects T cell responses to cancer immunotherapy
Official title: DUSP2 in Negative Regulation of Cytotoxic T Cell Responses to Immunotherapy
Funded at Mayo Clinic Rochester · NIH-11075119 · Data updated 2026-11-12
This study is looking at how a protein called DUSP2 affects the way a type of immune cell, known as CD8+ T cells, helps fight cancer during immunotherapy, with the goal of finding new ways to make these treatments work better for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $49,538 |
| NIH project number | 5F31CA287495-02 |
| Project ID | NIH-11075119 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients undergoing immunotherapy who may benefit from enhanced T cell responses.
✕Less likely to help
Patients who are not receiving immunotherapy or those with conditions unrelated to T cell function may not benefit from this research.
What this research studies
This research investigates the role of a protein called DUSP2 in regulating the effectiveness of immunotherapy for cancer patients. It focuses on a specific type of immune cell, the CD8+ T cell, which is crucial for attacking tumors. By studying how DUSP2 influences these cells' ability to respond to treatment, the researchers aim to identify new therapeutic targets that could enhance the effectiveness of immunotherapy. The approach includes analyzing human T cells and using advanced techniques like single-cell RNA sequencing to gather detailed insights.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments for cancer patients, potentially increasing the number of patients who respond positively to these therapies.
How similar studies have gone: Previous research has shown promising results regarding the role of DUSP2 in T cell function, indicating that this area of investigation could lead to significant advancements in cancer treatment.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Dellacecca, Emilia R — Mayo Clinic Rochester
- Study coordinator: Dellacecca, Emilia R
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.